Geron posts corporate presentation outlining RYTELO commercial strategy, growth plans

Geron Corporation

GERN

0.00

Geron reaffirmed 2026 guidance for RYTELO net product revenue of $220 million-$240 million.
Total operating expenses expected at $230 million-$240 million.
Q1 2026 RYTELO net revenue reported at $51.8 million, up 31% from Q1 2025.
Phase 3 IMpactMF trial in relapsed or refractory myelofibrosis targets interim analysis in 2H 2026, final analysis in 2H 2028.
RYTELO positioned for second-line lower-risk MDS, with company estimating about 8,000 addressable US patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.